SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/
The scientific team of SunRock Biopharma.
SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock will benefit from Chime Biologics’ global-standard GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones.
“We are proud to collaborate with SunRock Biopharma on this promising anti-CCR9 antibody (SRB5) for inflammatory bowel disease, a condition that significantly impacts patients worldwide. This partnership reflects our commitment to applying our global-standard quality and comprehensive experiences in manufacturing biologics to accelerate the development of innovative therapies. We look forward to contributing to the long-term mission of SunRock Biopharma to develop innovative antibodies against highly invasive tumors with an urgent clinical need in oncology,” said Dr.Jimmy Wei, President of Chime Biologics.
Dr. Laureano Simón, CEO of SunRock Biopharma, added “This collaboration with Chime Biologics reinforces our strategy of working with world-class partners across every stage of development. Chime’s technical expertise and industrial quality standards will help us scale SRB5 under optimal conditions. SRB5 has a distinctive biological profile that could transform the therapeutic landscape in IBD and potentially in highly aggressive CCR9-expressing tumors. This agreement is a critical step toward clinical validation.”
About SunRock Biopharma
SunRock Biopharma is a Spanish biotechnology company developing first-in-class and best-in-class therapeutic antibodies targeting emerging disease drivers in oncology and immune-mediated inflammatory diseases. Its approach focuses on identifying targets with a strong role in tumor progression or inflammation, generating fully human or humanized antibodies with enhanced functional profiles, and advancing them toward early clinical stages for licensing to global pharma partners.
SunRock’s pipeline includes monoclonal antibodies, antibody-drug conjugates (ADCs), and other innovative formats. SunRock collaborates with academic institutions and industry partners across Europe, the U.S., and Asia.
More information: www.sunrockbiopharma.com
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers’ success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. For more information, please visit www.chimebiologics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251019831972/en/
Contacts
Press Contact – SunRock Biopharma
media@sunrockbiopharma.com
Press Contact – Chime Biologics
info@chimebiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Study: 73% of Shoppers Using AI in Shopping Journey - But Merchants Face New Agentic Commerce Risks20.10.2025 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud prevention and risk intelligence, today released findings from a survey highlighting the increased adoption of agentic shopping, and the rising threat it poses to merchants. Based on a global survey of more than 5,000 consumers, the research reveals a defining moment for ecommerce: nearly three in four shoppers (73%) are already using AI in their shopping journey. Shoppers are embracing AI assistants like ChatGPT for product ideas (45%), to summarize reviews (37%), and to compare prices (32%). While only 13% say they’ve completed a purchase after being referred by an AI assistant, 70% are at least somewhat comfortable with an AI agent making purchases on their behalf. More than half (58%) are likely to use these tools for gift shopping this year, marking the beginning of the first truly AI-powered holiday season, where convenience for consumers may come with heightened exposure for merchants who may bear the liability for this
AI-Driven Cyber Threats Are the Biggest Concern for Cybersecurity Professionals Going Into 2026, Finds New ISACA Research20.10.2025 14:58:00 EEST | Press release
Over half (51%) of European IT and cybersecurity professionals fear AI-driven cyber threats and deepfakes will keep them up at night next year, according to new ISACA research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020612551/en/ What’s driving this concern is a lack of preparedness for AI-related risks across the industry. Only 14% of respondents feel their organisation is very prepared to manage the risks associated with generative AI solutions in 2026. The majority (82%) feel they are only somewhat prepared, not very prepared, or not prepared at all. Tech professionals clearly perceive AI-driven threats as the most concerning, yet other threats persist which pose risks to business continuity. Other than AI-driven threats, regulatory complexity and compliance risks (38%), supply chain vulnerabilities (37%), and the failure to detect and respond to a breach, causing irreparable harm to the business (35%) were als
IonQ Partners with Italy’s National Strategy for Quantum Technology; Co-Founds Q-Alliance to Jointly Create Quantum Hub20.10.2025 14:05:00 EEST | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance brings together public and private partners committed to building a future-forward quantum ecosystem. The initiative – launched at the ComoLake2025 Digital Innovation Forum – combines the advanced quantum technology and expertise of IonQ with support from leading Italian scientific institutions and governmental stakeholders. Q-Alliance aims to accelerate breakthroughs in science, support Italy’s industrial transition, and ensure long-term digital sovereignty. “IonQ enables a fantastic opportunity for Italy to lead a ‘Quantum Renaissance’ with the potential to transform not only the country but the EU,” said Niccolo de Masi, Chairman and CEO of IonQ. “Through this landmark quantum collabora
Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 13:01:00 EEST | Press release
Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective cooling. The outcome is less pipe clutter, and less noise for mo
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will be presented, highlighting promising antitumor activity and a generally manageable safety and tolerability profile in patients with advanced solid tumors. “The results presented at ESMO 2025 strengthen the evidence base for TEVIMBRA in lung cancer, with consistent survival ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom